Prostate Cancer

Prostate cancer is the most common non-skin cancer in the United States and the third most common cancer worldwide. More than 1 million men in the United States have prostate cancer and it is the second leading cause of cancer death amongst men after lung cancer. In 2009, an estimated 192,280 new cases are expected to be diagnosed and approximately 27,360 men are expected to die from the disease. Castration-resistant prostate cancer (CRPC) is defined as prostate cancer that continues to grow despite all standard-of-care hormonal (anti-androgen) therapies. Patients with castration-resistant (also known as hormone-refractory) prostate cancer have few treatment options and a poor prognosis.

Prostate Cancer

Prostate cancer is one of the most common cancers in men, with more than 40,000 new cases diagnosed every year in the UK. This is usually a slow growing cancer and most men do not notice the symptoms until the cancer has become large enough to press against the urethra and interfere with urination.

Differentiating between prostate cancer and prostate enlargement

Precancerous conditions of the prostate

Survival rates of prostate cancer

Causes of prostatitis

The International Prostate Symptoms Score (IPSS)

Treatment of Benign Prostatic Hyperplasia (BHP)

Prostate Cancer and Diet

Vasectomy and prostate cancer: Myth or reality?

Radiation therapy for prostate cancer

Prostate Cancer and Exercise

Prostate Cancer Partin Tables

See more featured articles »

Choosing the best treatment of prostate cancer - by stage

Rectal Examination for Prostate Cancer

Prostate cancer prevention

Gold Nanoparticles Use in Prostate Cancer

Recent Genetic Breakthroughs in Prostate Cancer Research

Prostate Cancer Staging

Can Curcumin Prevent or Treat Prostate Cancer?

Prostate Biopsy

Prostate Cancer Cell Dormancy and Activation

Prostate Cancer Epidemiology

Prostate Cancer Risk Factors

What is Prostatectomy?

Prostate cancer alternative and complementary therapies

Prostate Cancer Epidemiology Worldwide

What is the PCA3 Test?

The Prostate

Prostate Cancer Screening

Gallium Ga 68-labeled PSMA-11 PET/CT Imaging for Prostate Cancer

Brachytherapy for Prostate Cancer

Cryosurgery for prostate cancer

What is medical castration?

PSA Test in Men Who Have Been Treated for Prostate Cancer

What is the Gleason Score?

What Should You Avoid Before a PSA Test?

Hormonal therapy for prostate cancer

Single Nucleotide Polymorphisms and Prostate Cancer

Prostate Cancer Questions

Symptoms of Benign Prostatic Hyperplasia (BHP)

Should MRI be Used to Diagnose Prostate Cancer?

What is the PSA Test?

What is benign prostatic hyperplasia?

Prostate Cancer and Genetics

Prostate cancer complications

PSA False Positive and False Negative Results

Causes of benign prostatic hyperplasia

Prostatitis symptoms

What is Prostatitis?

Palliative treatment and end of life care for prostate cancer

Diagnosis of Benign Prostatic Hyperplasia (BPH)

Diagnosis of prostatitis

Breakthroughs in Prostate Cancer Treatments

What is TURP?

Prostate Cancer Research

Treatment of prostatitis

Prostate Cancer Treatment

Prostate Cancer Symptoms

Life after prostate cancer treatment

Types of PSA Test

Prostate Cancer Diagnosis

Latest Prostate Cancer News and Research

Prostate cancer overdiagnosis risk increases substantially in older men

Researchers at Queen Mary University of London have found that the likelihood of prostate cancer overdiagnosis – the detection of a cancer that would never have been diagnosed during a patient's lifetime but for PSA screening – is low in younger men but rises substantially with old age.

22 Apr 2026

Federal housing support improves survival odds for prostate cancer patients

Older men with prostate cancer who receive federal housing assistance at the time they are first diagnosed have better two-year survival chances compared to demographically and clinically similar men without that assistance, new UCLA-led research suggests.

22 Apr 2026

New method predicts cancer patient survival using advanced molecular data

Oregon Health & Science University researchers have developed a first-of-its-kind method to predict cancer patient survival using advanced molecular data from individual cells.

21 Apr 2026

Why do the deadliest cancers still get less NIH research funding?

Researchers found that NIH funding for major US cancers does not consistently align with lethality, with highly fatal cancers such as pancreatic cancer and small-cell lung cancer receiving far less funding per estimated death than breast or prostate cancer. The study argues that incidence alone is not enough and that funding decisions should better incorporate mortality, survival, and mortality-to-incidence ratios.

21 Apr 2026

Scientists discover BRCA links to head and neck cancer risks

An international group led by researchers from the RIKEN Center for Integrative Medical Sciences (IMS) in Japan have discovered associations between pathogenic variants of the BRCA 1 and 2 genes and four types of cancer. Published in ESMO Open, the findings expand the potential for personalized medicine to several cancer types that currently have limited treatment options and poor prognoses.

17 Apr 2026

New grant funds AI search for genetic targets to treat Alzheimer's

With a new $6.2 million, five-year grant from the National Institute on Aging, researchers at Case Western Reserve University will use artificial intelligence (AI) and machine learning to identify possible genetic targets to treat Alzheimer's disease.

15 Apr 2026

Prostate cancer patients recover faster with TULSA than robotic surgery

A new randomized clinical trial found that men with localized, intermediate‑risk prostate cancer recovered faster and experienced less short‑term impact on their daily lives when treated with MRI‑guided, transurethral ultrasound ablation (TULSA) compared with robotic prostate surgery.

13 Apr 2026

Targeting super-enhancer mechanisms offers new strategies for cancer therapy

Super-enhancers (SEs) are large clusters of transcriptional regulatory elements that drive oncogene expression, maintain malignancy, and create "transcriptional addiction" in cancer.

13 Apr 2026

Pseudogene lncRNAs regulate cancer stem cell behavior and signaling

Cancer stem cells (CSCs), a critical subpopulation within tumors, drive cancer initiation, progression, metastasis, relapse, and resistance to therapy due to their innate capacity for self-renewal and differentiation.

11 Apr 2026

Talc not contaminated with asbestos shows no link to cancer

In a systematic review and meta-analysis, researchers found that occupational exposure to talc that is not contaminated with asbestos is not associated with an increase in the risk of lung cancer, mesothelioma, or laryngeal cancer.

10 Apr 2026

Metformin boosts an exercise-linked metabolite and may help control weight in prostate cancer patients

Metformin raised the exercise-linked metabolite Lac-Phe in prostate cancer patients across disease stages and treatment settings, while Lac-Phe itself did not predict anticancer response. Patients in the BIMET-1 metformin arm also showed better weight management during anti-androgen therapy, highlighting a possible metabolic benefit relevant to prostate cancer care.

7 Apr 2026

New technique can simultaneously treat lung cancer and muscle-wasting condition

Researchers at Oregon State University have developed a technique for simultaneously treating lung cancer and a serious muscle-wasting condition that often accompanies it.

6 Apr 2026

Metformin mimics exercise-related metabolic effects in prostate cancer patients

A new study has found that metformin, a widely prescribed diabetes drug, may mimic one of exercise's core biological effects in men with prostate cancer, raising levels of a molecule tied to energy balance and weight control even when patients are inactive.

6 Apr 2026

PSMA therapy may postpone hormone treatment in prostate cancer patients

Where previous research showed that PSMA therapy for prostate cancer can prolong the lives of patients who have exhausted all other treatment options, a new study now demonstrates that the therapy is also effective in an earlier stage of the disease.

30 Mar 2026

ATLAS platform enables realistic study of metastatic cancer clusters

Metastasis, the spread of cancer from a primary tumor to other parts of the body, is difficult to study in the lab, in part because researchers lack reliable ways to recreate the conditions cancer cells encounter as they travel through the bloodstream.

26 Mar 2026

Men show major gaps in male fertility knowledge, study finds

A study of 156 adult men found that knowledge about male fertility was generally low across both medical and lifestyle-related topics, with only 5 of 25 questions answered correctly by most respondents. Older men, those with a medical background, and those with suspected or treated infertility tended to score higher, while supplement use was common despite limited fertility literacy.

26 Mar 2026

Estradiol patches as effective as injections for locally advanced prostate cancer

Hormone patches are as good at controlling locally advanced prostate cancer as the injections typically used to deliver hormone therapy, according to the results of a large clinical trial led by UCL (University College London) researchers.

25 Mar 2026

Blood pressure drug boosts effectiveness of cancer therapy

In a new Dartmouth Cancer Center (DCC) study led by clinical researcher Tyler J. Curiel, MD, MPH, FACP, investigators found that the FDA-approved blood pressure drug telmisartan can significantly enhance the cancer-killing activity of the targeted therapy olaparib, potentially expanding its use to many more patients.

25 Mar 2026

Detailed cell atlas reveals earliest changes in prostate cancer

Prostate cancer affects one in five Australian men, making it the most common cancer in the country.

25 Mar 2026

Systematic review identifies stress-induced biological triggers in oncology

Stress is a constant companion in the oncologist's office. It appears at the time of diagnosis, increases with each stage of treatment, and often does not resolve even after therapy formally ends. It accompanies therapeutic decisions, waiting for test results, fear of recurrence, and changes in daily functioning. Studies show that chronic stress can trigger biological processes that promote disease progression and weaken the body's defenses.

25 Mar 2026